^
Association details:
| Biomarker: | KRAS deletion |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
Excerpt:
Cell lines with a KRAS (V12) mutation and KRAS gains or loss (n=7) are ∼10 times more resistant than those having neither a KRAS (V12) mutation nor KRAS CNV (n=14).
DOI:
10.1038/bjc.2014.475
